|
|
|
|
|
by gus_massa
1611 days ago
|
|
Note that the original article and the article you posted are not randomized controlled trails. Does the people that accept to take Ivermectin more cautious than the people that don't? Does young people more likely to try? There are too many variables and it's just too hard to know without a RCT. Also, the problem with these types of studies is that bad outcomes are sometimes not published. Nobody want to write an article with the title "We used Ivermectin and we killed an additional statistical significant number of coworkers" https://en.wikipedia.org/wiki/Reporting_bias For a RCT it's necessary more paperwork and authorizations and ideally preregistering. So that increase the chance of that they must write the final paper. Also, as the PG noted the "peer review" of this site is not the traditional peer review of a normal journal. For example, the title says "Observational Study of 223,128 Subjects" but later it says "a total of 159,561 subjects were included in the analysis". The main part of the difference is that they report in the title the total number of inhabitants, but for the analysis they use only the ones that have more than 18 years old. It's not a smoking gun, but at least it's a small red flag. |
|
I found the other study I wanted to reference: https://media.marinomed.com/8b/7a/c7/nota-journal-of-biomedi...
> No patients of the 788 treated with IVERCAR tested positive for CoVid 19 during the study.
Again, I don't know, but it smells like SOMETHING
What I "believe" about this is prophylaxis, I think this is why there are no results once symptoms are really apparent. This might be why the point about Ivermectin being antiviral only at very high doses doesn't hold, maybe it provides protection when there is only a tiny exposure to the virus. Heck, there's even a result circulating that cannabis was protective... Who knows?